IL1B and migraine disorder: Pharmacological blocking NLRP3 (Table 2) or IL-1β with the NLRP3 antagonist MCC950 or IL-1ra not only improved NTG-induced hyperalgesia, but also inhibited the biomarkers related to central sensitization of migraine in TNC, such as p-ERK, c-Fos, and CGRP.